SCK CEN

POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

Retrieved on: 
Tuesday, February 1, 2022
CEO, IND, Risk, Patient, Feedback, NETS, Private Securities Litigation Reform Act, MCRPC, Prostate cancer, NASDAQ, TerraPower, Isotope, PSMA, Lung, Clinical trial, Ytterbium, SEC, Intention, Actinium-225, SNMMI, SPLASH, Annual general meeting, Arbutus Biopharma, COVID-19, Population, Cancer, DOE, SCK CEN, Company, American Physical Society, Investigational New Drug, GLOBE, Forward-looking statement, Kidney, SCK, NDA, Ovary, Terminology, Wilms' tumor, Radiopharmaceutical, Medical imaging, Pharmaceutical industry, Lithium

INDIANAPOLIS, Ind., Feb. 01, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced business progress updates, including the completion of its Indianapolis, Indiana production facility, as well as the scheduled presentation of dosimetry data from the lead-in cohort of the Company’s Phase 3 trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting, taking place February 25-27, 2022.

Key Points: 
  • With our facility now operational, POINT is one of the only pharmaceutical companies globally positioned to manufacture radiopharmaceuticals on a commercial scale, said Dr. Joe McCann, CEO of POINT Biopharma.
  • Lu-177 production capability will be the backbone of the companys clinical and commercial production and provides supply chain redundancy.
  • About POINT Biopharma Global Inc.
    POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/ .

POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)

Retrieved on: 
Wednesday, November 24, 2021
Neutron, Patient, Private Securities Litigation Reform Act, SCK CEN, Prostate cancer, Safety, CEO, Environment, Radiopharmaceutical, Technology, Publication, Forward-looking statement, Biopharma LLC, MCRPC, Radionuclide, SPLASH, Cancer, SEC, CEN, COVID-19, SCK, Medicine, Research, Risk, GLOBE, Terminology, Radioactive decay, Intention, Nuclear medicine, NASDAQ, Tuwaitha Nuclear Research Center, Â, Medical imaging

SCK CENs significant scientific development experience and research capabilities have enabled them to develop innovative and scalable technology for the efficient production of n.c.a.

Key Points: 
  • SCK CENs significant scientific development experience and research capabilities have enabled them to develop innovative and scalable technology for the efficient production of n.c.a.
  • Eric van Walle, Director General of SCK CEN, added By leveraging our long history and deep expertise in nuclear technology, we strive to be an indispensable player in the production and distribution of radioisotopes for nuclear medicine.
  • Spanning sixty-five years of experience in nuclear research and nuclear technology, SCK CEN is one of the largest research institutions in Belgium.
  • SCK CEN's research activities focus on three main areas: the safety of nuclear installations, the development of nuclear medicine and protecting people and the environment from ionizing radiation.

First Cyclotron Removed from Seneffe Production Facility by SCK CEN

Retrieved on: 
Monday, October 18, 2021
General manager, Australian Securities Exchange, Industry, Publication, Environment, LinkedIn, ASX, SCK, Cancer, TGA, Employment, CEN, Degenerative disease, SCK CEN, Nuclear medicine, Cyclotron, MTR, Australian Radiation Protection and Nuclear Safety Agency, News, Patient, GLOBE, Economic development, Radioactive decay, Safety, TLX, Research, Partnership, AFCN, Saclay Nuclear Research Centre, Fine chemical

The cyclotron weighing approximately 22 tonnes was successfully removed by SCK CEN, a leader in nuclear safety and facility decommissioning.

Key Points: 
  • The cyclotron weighing approximately 22 tonnes was successfully removed by SCK CEN, a leader in nuclear safety and facility decommissioning.
  • Once the second cyclotron has been removed later this year, Telix will be able to formally commence the build-out of a new state-of-the-art facility for medical radioisotope production and drug product manufacturing.
  • The sooner Telix can start production, the sooner these important products can reach cancer patients," stated Michel Estas, decommissioning expert at SCK CEN.
  • Sbastien Linard de Guertechin, General Manager of the Seneffe Facility stated, Telix is delighted to be working with SCK CEN for the decommissioning.